<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33606761</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>04</Day></DateCompleted><DateRevised><Year>2021</Year><Month>08</Month><Day>04</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>2</Issue><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Amyotrophic Lateral Sclerosis (ALS) prediction model derived from plasma and CSF biomarkers.</ArticleTitle><Pagination><StartPage>e0247025</StartPage><MedlinePgn>e0247025</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0247025</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0247025</ELocationID><Abstract><AbstractText>Amyotrophic Lateral Sclerosis (ALS) is a degenerative disorder of motor neurons which leads to complete loss of movement in patients. The only FDA approved drug Riluzole provides only symptomatic relief to patients. Early Diagnosis of the disease warrants the importance of diagnostic and prognostic models for predicting disease and disease progression respectively. In the present study we represent the predictive statistical model for ALS using plasma and CSF biomarkers. Forward stepwise (Binary likelihood) Logistic regression model is developed for prediction of ALS. The model has been shown to have excellent validity (94%) with good sensitivity (98%) and specificity (93%). The area under the ROC curve is 99.3%. Along with age and BMI, VEGF (Vascular Endothelial Growth Factor), VEGFR2 (Vascular Endothelial Growth Factor Receptor 2) and TDP43 (TAR DNA Binding Protein 43) in CSF and VEGFR2 and OPTN (Optineurin) in plasma are good predictors of ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Khosla</LastName><ForeName>Radhika</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Neuroscience Research Lab, Post Graduate Institute of Medical Education and Research, Chandigarh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rain</LastName><ForeName>Manjari</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Neuroscience Research Lab, Post Graduate Institute of Medical Education and Research, Chandigarh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Suresh</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Statistics, Panjab University, Chandigarh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anand</LastName><ForeName>Akshay</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-9003-3532</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Neuroscience Research Lab, Post Graduate Institute of Medical Education and Research, Chandigarh, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>02</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042241" MajorTopicYN="N">Early Diagnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015233" MajorTopicYN="Y">Models, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>10</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>1</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>2</Month><Day>19</Day><Hour>17</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>2</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33606761</ArticleId><ArticleId IdType="pmc">PMC7894922</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0247025</ArticleId><ArticleId IdType="pii">PONE-D-20-32007</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Talbott E, Malek A, Lacomis D. The epidemiology of amyotrophic lateral sclerosis In: Handbook of clinical neurology. Vol 138 Elsevier; 2016:225&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pubmed">27637961</ArticleId></ArticleIdList></Reference><Reference><Citation>Manjaly ZR, Scott KM, Abhinav K, et al. The sex ratio in amyotrophic lateral sclerosis: a population based study. Amyotrophic Lateral Sclerosis. 2010;11(5):439&#x2013;442. 10.3109/17482961003610853</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482961003610853</ArticleId><ArticleId IdType="pmc">PMC6485484</ArticleId><ArticleId IdType="pubmed">20225930</ArticleId></ArticleIdList></Reference><Reference><Citation>Borras-Blasco J, Plaza-Mac&#xed;as I, Navarro-Ruiz A, Peris-Marti J, Anton-Cano A. Riluzole as a treatment for amyotrophic lateral sclerosis. Revista de neurologia. 1998;27(160):1021&#x2013;1027.</Citation><ArticleIdList><ArticleId IdType="pubmed">9951030</ArticleId></ArticleIdList></Reference><Reference><Citation>Su XW, Simmons Z, Mitchell RM, Kong L, Stephens HE, Connor JR. Biomarker-based predictive models for prognosis in amyotrophic lateral sclerosis. JAMA neurology. 2013. December 1;70(12):1505&#x2013;11. 10.1001/jamaneurol.2013.4646</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.4646</ArticleId><ArticleId IdType="pubmed">24145899</ArticleId></ArticleIdList></Reference><Reference><Citation>Magnus T, Beck M, Giess R, Puls I, Naumann M, Toyka KV. Disease progression in amyotrophic lateral sclerosis: predictors of survival. Muscle &amp; Nerve: Official Journal of the American Association of Electrodiagnostic Medicine. 2002. May;25(5):709&#x2013;14. 10.1002/mus.10090</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.10090</ArticleId><ArticleId IdType="pubmed">11994965</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor AA, Fournier C, Polak M, Wang L, Zach N, Keymer M, et al. Pooled Resource Open&#x2010;Access ALS Clinical Trials Consortium. Predicting disease progression in amyotrophic lateral sclerosis. Annals of Clinical and Translational Neurology. 2016. November;3(11):866&#x2013;75. 10.1002/acn3.348</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.348</ArticleId><ArticleId IdType="pmc">PMC5099532</ArticleId><ArticleId IdType="pubmed">27844032</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong ML, Tan PF, Holbrook JD. Predicting functional decline and survival in amyotrophic lateral sclerosis. PLoS One. 2017. April 13;12(4):e0174925 10.1371/journal.pone.0174925</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0174925</ArticleId><ArticleId IdType="pmc">PMC5390993</ArticleId><ArticleId IdType="pubmed">28406915</ArticleId></ArticleIdList></Reference><Reference><Citation>Westeneng HJ, Debray TP, Visser AE, van Eijk RP, Rooney JP, Calvo A, et al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. The Lancet Neurology. 2018. May 1;17(5):423&#x2013;33. 10.1016/S1474-4422(18)30089-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30089-9</ArticleId><ArticleId IdType="pubmed">29598923</ArticleId></ArticleIdList></Reference><Reference><Citation>Modgil S, Khosla R, Tiwari A, Sharma K, Anand A. Association of Plasma biomarkers for Angiogenesis and Proteinopathy in Indian Amyotrophic Lateral Sclerosis Patients. Journal of Neurosciences in Rural Practice. 2020. August 20 10.1055/s-0040-1714314</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0040-1714314</ArticleId><ArticleId IdType="pmc">PMC7595776</ArticleId><ArticleId IdType="pubmed">33144793</ArticleId></ArticleIdList></Reference><Reference><Citation>Khosla R, Rain M, Chawathey S, Modgil S, Tyagi R, Thakur K, et al. Identifying putative cerebrospinal fluid biomarkers of amyotrophic lateral sclerosis in a north Indian population. Muscle &amp; Nerve. 2020. October;62(4):528&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">32696574</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta PK, Prabhakar S, Sharma S, Anand A. A predictive model for amyotrophic lateral sclerosis (ALS) diagnosis. Journal of the neurological sciences. 2012. January 15;312(1&#x2013;2):68&#x2013;72. 10.1016/j.jns.2011.08.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2011.08.021</ArticleId><ArticleId IdType="pubmed">21907354</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR,Miller RG, Swash M, Munsat TL; World Federation of Neurology Research Group onMotor Neuron Diseases. El Escorial revisited:revised criteria for the diagnosis of amyotrophiclateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1(5):293&#x2013;299. 10.1080/146608200300079536</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Agosta F, Al-Chalabi A, Filippi M, et al. The El Escorial criteria: strengths and weaknesses. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 2015;16(1&#x2013;2):1&#x2013;7. 10.3109/21678421.2014.964258</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.964258</ArticleId><ArticleId IdType="pubmed">25482030</ArticleId></ArticleIdList></Reference><Reference><Citation>Corcia P, Pradat PF, Salachas F, et al. Causes of death in a post&#x2010;mortem series of ALS patients. Amyotrophic Lateral Sclerosis. 2008;9(1):59&#x2013;62. 10.1080/17482960701656940</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960701656940</ArticleId><ArticleId IdType="pubmed">17924236</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Chi&#xf2; A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. Nature neuroscience. 2014;17(1):17 10.1038/nn.3584</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3584</ArticleId><ArticleId IdType="pmc">PMC4544832</ArticleId><ArticleId IdType="pubmed">24369373</ArticleId></ArticleIdList></Reference><Reference><Citation>Oosthuyse B, Moons L, Storkebaum E, et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nature genetics. 2001;28(2):131 10.1038/88842</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/88842</ArticleId><ArticleId IdType="pubmed">11381259</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambrechts D, Storkebaum E, Morimoto M, et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nature genetics. 2003;34(4):383 10.1038/ng1211</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1211</ArticleId><ArticleId IdType="pubmed">12847526</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta PK, Prabhakar S, Abburi C, Sharma NK, Anand A. Vascular endothelial growth factor-A and chemokine ligand (CCL2) genes are upregulated in peripheral blood mononuclear cells in Indian amyotrophic lateral sclerosis patients. Journal of neuroinflammation. 2011. December 1;8(1):114 10.1186/1742-2094-8-114</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-8-114</ArticleId><ArticleId IdType="pmc">PMC3177897</ArticleId><ArticleId IdType="pubmed">21906274</ArticleId></ArticleIdList></Reference><Reference><Citation>Brockington A, Wharton SB, Fernando M, et al. Expression of vascular endothelial growth factor and its receptors in the central nervous system in amyotrophic lateral sclerosis. Journal of Neuropathology &amp; Experimental Neurology. 2006;65(1):26&#x2013;36. 10.1097/01.jnen.0000196134.51217.74</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.jnen.0000196134.51217.74</ArticleId><ArticleId IdType="pubmed">16410746</ArticleId></ArticleIdList></Reference><Reference><Citation>Vijayalakshmi K, Ostwal P, Sumitha R, Shruthi S, Varghese AM, Mishra P, et al. Role of VEGF and VEGFR2 receptor in reversal of ALS-CSF induced degeneration of NSC-34 motor neuron cell line. Molecular neurobiology. 2015. June 1;51(3):995&#x2013;1007. 10.1007/s12035-014-8757-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-014-8757-y</ArticleId><ArticleId IdType="pubmed">24880751</ArticleId></ArticleIdList></Reference><Reference><Citation>Crivello M, O&#x2019;riordan SL, Woods I, Cannon S, Halang L, Coughlan KS, et al. Pleiotropic activity of systemically delivered angiogenin in the SOD1G93A mouse model. Neuropharmacology. 2018;133:503&#x2013;11. 10.1016/j.neuropharm.2018.02.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2018.02.022</ArticleId><ArticleId IdType="pubmed">29486168</ArticleId></ArticleIdList></Reference><Reference><Citation>Povysheva T, Shmarov M, Logunov D, Naroditsky B, Shulman I, Ogurcov S, et al. Post-spinal cord injury astrocyte-mediated functional recovery in rats after intraspinal injection of the recombinant adenoviral vectors Ad5-VEGF and Ad5-ANG. Journal of neurosurgery Spine. 2017;27(1):105&#x2013;15. 10.3171/2016.9.SPINE15959</Citation><ArticleIdList><ArticleId IdType="doi">10.3171/2016.9.SPINE15959</ArticleId><ArticleId IdType="pubmed">28452633</ArticleId></ArticleIdList></Reference><Reference><Citation>Anand A, Thakur K, Gupta PK. ALS and oxidative stress: the neurovascular scenario. Oxidative medicine and cellular longevity. 2013. October;2013 10.1155/2013/635831</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/635831</ArticleId><ArticleId IdType="pmc">PMC3866720</ArticleId><ArticleId IdType="pubmed">24367722</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollari E, Goldsteins G, Bart G, Koistinaho J, Giniatullin R. The role of oxidative stress in degeneration of the neuromuscular junction in amyotrophic lateral sclerosis. Frontiers in cellular neuroscience. 2014. May 13;8:131 10.3389/fncel.2014.00131</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2014.00131</ArticleId><ArticleId IdType="pmc">PMC4026683</ArticleId><ArticleId IdType="pubmed">24860432</ArticleId></ArticleIdList></Reference><Reference><Citation>Akizuki M, Yamashita H, Uemura K, Maruyama H, Kawakami H, Ito H, et al. Optineurin suppression causes neuronal cell death via NF&#x2010;&#x3ba;B pathway. Journal of neurochemistry. 2013;126(6):699&#x2013;704. 10.1111/jnc.12326</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.12326</ArticleId><ArticleId IdType="pubmed">23721573</ArticleId></ArticleIdList></Reference><Reference><Citation>Winton MJ, Igaz LM, Wong MM, Kwong LK, Trojanowski JQ, Lee VM-Y. Disturbance of nuclear and cytoplasmic Tar DNA binding protein (TDP-43) induces disease-like redistribution, sequestration and aggregate formation. Journal of Biological Chemistry. 2008. 10.1074/jbc.M800342200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M800342200</ArticleId><ArticleId IdType="pmc">PMC2442318</ArticleId><ArticleId IdType="pubmed">18305110</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagata T, Nagano I, Shiote M, Narai H, Murakami T, Hayashi T, et al. Elevation of MCP-1 and MCP-1/VEGF ratio in cerebrospinal fluid of amyotrophic lateral sclerosis patients. Neurological research. 2007;29(8):772&#x2013;6. 10.1179/016164107X229795</Citation><ArticleIdList><ArticleId IdType="doi">10.1179/016164107X229795</ArticleId><ArticleId IdType="pubmed">17672928</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel JS, Beers DR, Sikl&#xf3;s L, Appel SH. The chemokine MCP-1 and the dendritic and myeloid cells it attracts are increased in the mSOD1 mouse model of ALS. Molecular and Cellular Neuroscience. 2006;31(3):427&#x2013;37. 10.1016/j.mcn.2005.10.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2005.10.016</ArticleId><ArticleId IdType="pubmed">16337133</ArticleId></ArticleIdList></Reference><Reference><Citation>Anand A, Sharma NK, Gupta A, Prabhakar S, Sharma SK, Singh R, et al. Single nucleotide polymorphisms in MCP-1 and its receptor are associated with the risk of age related macular degeneration. PloS one. 2012. November 21;7(11):e49905 10.1371/journal.pone.0049905</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0049905</ArticleId><ArticleId IdType="pmc">PMC3503775</ArticleId><ArticleId IdType="pubmed">23185481</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma NK, Prabhakar S, Gupta A, Singh R, Gupta PK, Gupta PK, et al. New biomarker for neovascular age-related macular degeneration: eotaxin-2. DNA and cell biology. 2012. November 1;31(11):1618&#x2013;27. 10.1089/dna.2012.1786</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/dna.2012.1786</ArticleId><ArticleId IdType="pubmed">23025269</ArticleId></ArticleIdList></Reference><Reference><Citation>Anand A, Gupta PK, Sharma NK, Prabhakar S. Soluble VEGFR1 (sVEGFR1) as a novel marker of amyotrophic lateral sclerosis (ALS) in the North Indian ALS patients. European Journal of Neurology. 2012. May;19(5):788&#x2013;92. 10.1111/j.1468-1331.2011.03548.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2011.03548.x</ArticleId><ArticleId IdType="pubmed">21978169</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma NK, Gupta A, Prabhakar S, Singh R, Bhatt AK, Anand A. CC chemokine receptor-3 as new target for age-related macular degeneration. Gene. 2013. July 1;523(1):106&#x2013;11. 10.1016/j.gene.2013.03.052</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gene.2013.03.052</ArticleId><ArticleId IdType="pubmed">23566847</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamal Sharma N, Gupta A, Prabhakar S, Singh R, Sharma S, Anand A. Single nucleotide polymorphism and serum levels of VEGFR2 are associated with age related macular degeneration. Current neurovascular research. 2012. November 1;9(4):256&#x2013;65. 10.2174/156720212803530681</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156720212803530681</ArticleId><ArticleId IdType="pubmed">23030506</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma NK, Gupta A, Prabhakar S, Singh R, Sharma SK, Chen W, et al. Association between CFH Y402H polymorphism and age related macular degeneration in North Indian cohort. PloS one. 2013. July 29;8(7):e70193 10.1371/journal.pone.0070193</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0070193</ArticleId><ArticleId IdType="pmc">PMC3726372</ArticleId><ArticleId IdType="pubmed">23922956</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>